Sector News

GlaxoSmithKline helps immunometabolism startup Sitryx to $30M round

October 10, 2018
Life sciences

GlaxoSmithKline has helped Sitryx to a $30 million (€26 million) funding round. Newly formed British biotech Sitryx will use the money and its relationship with GSK to move immunometabolism assets toward human testing.

Sitryx is built upon research into the role metabolic pathways play in the function of immune cells and, by extension, the development of cancers and autoimmune diseases. By designing drugs that act on these pathways, Sitryx and its transatlantic syndicate of founding scientists think they can correct immune cell function and stop tumor growth.

GSK became aware of the research through an initiative that connects it to immunology academics. Seeing the potential, GSK’s drug discovery and chemistry teams are working with Sitryx and sharing technologies and chemical matter with the startup.

The Big Pharma is one of a clutch of well-known investors that helped get Sitryx off the ground. SV Health Investors, which provided initial seed funding, co-led the round with Sofinnova Partners. GSK and Longwood Fund chipped in cash too, giving Sitryx the means to advance one of its portfolio of oncology and immuno-inflammatory drugs to the cusp of the clinic.

“The funding round was sized to allow us to achieve one IND/CTA approval and, if projects progress as we anticipate, to initiate IND-enabling preclinical studies for a second program,” Sitryx CEO Neil Weir said.

Weir served as SVP of UCB Pharma until recently. The CEO joined a company that has already built up a portfolio of early-stage small molecules, proteolysis-targeting chimeras and topical formulations aimed at oncology and immuno-inflammatory indications.

The breadth of the portfolio factored into Weir’s decision to join Sitryx.

“Sitryx presented an opportunity for me to build on my pharmaceutical experiences, to lead an organization and work with an excellent set of founding scientists,” Weir said. “Having the confidence that sufficient funding would be generated to give a real opportunity to discover novel medicines was also important. And this is not a one-shot company, we have a portfolio of opportunities to develop here so I’m very excited about the company’s potential.”

By: Nick Paul Taylor
Source: Fierce Biotech

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach